Holen Sie sich die Stockscreener-App
14.28
2.07%
0.29
Handel nachbörslich:
14.40
0.12
+0.84%
Uniqure N V Aktie (QURE) Neueste Nachrichten
uniQure: Price And Value Have Caught Up (NASDAQ:QURE) - Seeking Alpha
uniQure shareholders approve executive compensation, board reappointments By Investing.com - Investing.com South Africa
uniQure shareholders approve executive compensation, board reappointments - Investing.com
uniQure (QURE) Appoints Kylie O'Keefe to Advance Global Strategy - GuruFocus
uniQure appoints Kylie O’Keefe as Chief Customer and Strategy Officer By Investing.com - Investing.com South Africa
uniQure appoints Kylie O’Keefe as Chief Customer and Strategy Officer - Investing.com India
uniQure Announces Appointment of Kylie O’Keefe as Chief Customer and Strategy Officer - GlobeNewswire
uniQure Prepares for Historic Huntington's Disease Treatment Launch with Key Executive Hire - Stock Titan
uniQure (NASDAQ:QURE) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Learn to Evaluate (QURE) using the Charts - news.stocktradersdaily.com
uniQure (QURE) Positioned for Growth Amid Regulatory Changes - GuruFocus
RFK Jr. looks to fast track rare disease drug approvals (updated) - Seeking Alpha
Bank of America Corp DE Has $1.22 Million Stock Holdings in uniQure (NASDAQ:QURE) - Defense World
Stock Traders Buy Large Volume of uniQure Call Options (NASDAQ:QURE) - Defense World
stifel reiterates buy rating on uniQure stock after CEO meeting By Investing.com - Investing.com UK
uniQure (NASDAQ:QURE) Short Interest Update - Defense World
H.C. Wainwright reaffirms Buy rating on uniQure stock after FDA meeting By Investing.com - Investing.com South Africa
H.C. Wainwright reaffirms Buy rating on uniQure stock after FDA meeting - Investing.com Australia
Chardan Capital Reaffirms Buy Rating for uniQure (NASDAQ:QURE) - MarketBeat
uniQure aligns with FDA on Huntington’s therapy path By Investing.com - Investing.com South Africa
uniQure provides regulatory update on AMT-130 for Huntington’s Disease - TipRanks
UniQure Reaches Alignment With FDA on Potential Huntington's Disease Gene Therapy - marketscreener.com
Transcript : UniQure N.V.Special Call - marketscreener.com
UniQure Provides Regulatory Update On Amt-130 For Huntington'S Disease - marketscreener.com
uniQure (QURE) Advances Gene Therapy for Huntington's Disease wi - GuruFocus
uniQure aligns with FDA on Huntington’s therapy path - Investing.com
uniQure (QURE) Advances Gene Therapy for Huntington's Disease with FDA Alignment | QURE Stock News - GuruFocus
uniQure Advances AMT-130 for Huntington's Disease with FDA Alignment, BLA Submission Planned for Q1 2026 - Nasdaq
uniQure Provides Regulatory Update on AMT-130 for Huntington’s Disease - GlobeNewswire
FDA Green Lights Accelerated Approval Plan for First-Ever Huntington's Disease Gene Therapy Treatment - Stock Titan
uniQure (NASDAQ:QURE) Given “Buy” Rating at Chardan Capital - Defense World
HC Wainwright maintains Buy rating on uniQure stock, $70 target By Investing.com - Investing.com UK
uniQure (NASDAQ:QURE) Receives Buy Rating from HC Wainwright - Defense World
QURE: HC Wainwright & Co. Reiterates Buy Rating for uniQure | QU - GuruFocus
uniQure presents case study of first patient dosed with AMT-260 - TipRanks
uniQure (QURE) Gains Support Following Positive Data from Epilep - GuruFocus
uniQure (QURE) Unveils Key Data from Gene Therapy Trial | QURE S - GuruFocus
uniQure early AMT-260 data encouraging, says H.C. Wainwright - TipRanks
uniQure (QURE) Unveils Key Data from Gene Therapy Trial | QURE Stock News - GuruFocus
uniQure Presents Clinical Case Study of First Patient Dosed - GlobeNewswire
uniQure Presents Clinical Case Study of First Patient Dosed with AMT-260 in Refractory Mesial Temporal Lobe Epilepsy (MTLE) | QURE Stock News - GuruFocus
Revolutionary Gene Therapy Cuts Epilepsy Seizures by 92% in First Patient DataUniQure's Breakthrough - Stock Titan
Down 40% in 2025, Should You Buy the Dip in Marvell Stock? - The Globe and Mail
Long Term Trading Analysis for (QURE) - news.stocktradersdaily.com
uniQure's AMT-130 Gene Therapy Warrants An Upgrade (NASDAQ:QURE) - Seeking Alpha
Northern Trust Corp Buys 1,923 Shares of uniQure (NASDAQ:QURE) - Defense World
Millennium Management LLC Cuts Position in uniQure (NASDAQ:QURE) - Defense World
uniQure (NASDAQ:QURE) Upgraded at Wall Street Zen - Defense World
uniQure N.V. (QURE) Stock Analysis: Exploring a 133.81% Potential Upside in Biotechnology - DirectorsTalk Interviews
Fed. Circ. Backs Pfizer Win Against Gene Therapy Patents - Law360
Stock Traders Purchase High Volume of Put Options on uniQure (NASDAQ:QURE) - Defense World
Analysts Set Expectations for uniQure FY2025 Earnings - Defense World
3 Top Genomics Stocks to Add to Your Portfolio in 2025 - Yahoo Finance
Ameriprise Financial Inc. Lowers Position in uniQure (NASDAQ:QURE) - Defense World
uniQure (NASDAQ:QURE) Stock Rating Upgraded by Cantor Fitzgerald - Defense World
(QURE) Trading Advice - news.stocktradersdaily.com
Chardan Capital Analysts Cut Earnings Estimates for uniQure - Defense World
Mayfair Gold: Advancing a Modern Vision for Gold Mining - The Globe and Mail
Beyond Medical Technologies Provides Update on 2024 Annual Filings - The Globe and Mail
Wall Street Analysts See a 161.51% Upside in uniQure (QURE): Can the Stock Really Move This High? - Yahoo Finance
1.45%
0.86%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):